Last reviewed · How we verify

NCT04332263

Neuromuscular Electrical Stimulation in ICU Patients

Terminated NA Last updated 10 June 2024
What this trial tests

NA trial testing Neuromuscular Electrical Stimulation - NMES in Intensive Care Unit Acquired Weakness in 56 participants. Terminated before completion.

Timeline
1 March 2022
Primary endpoint
1 March 2022
6 June 2024

Quick facts

Lead sponsorFederal University of Rio Grande do Sul
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment56
Start date1 March 2022
Primary completion1 March 2022
Estimated completion6 June 2024
Sites1 location across Brazil

Drugs / interventions tested

Conditions studied

Sponsor

Federal University of Rio Grande do Sul

Who can join

18 and older, any sex, with Intensive Care Unit Acquired Weakness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the present study is to evaluate the effects of neuromuscular electrical stimulation (NMES) combined with conventional physiotherapy (Experimental Group), compared to conventional physiotherapy only (Control Group) in critically ill Intensive Care Unit (ICU) patients, by means of a randomized controlled clinical trial. The investigators expect that the NMES program will be able to reduce muscle structure and function losses compared to control group, and will improve muscle quality faster, will reduce the ventilation time and the total time spent at the ICU, as well as improve functionality of these patients. In addition, the researchers expect to understand which mechanisms determine such adaptations in the musculoskeletal system of these patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Intensive Care Unit Acquired Weakness

Currently open trials in the same condition.

Other Federal University of Rio Grande do Sul trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04332263.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing